These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34058788)

  • 41. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
    Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
    Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
    Baumann N; Arndt C; Petersen J; Lustig M; Rösner T; Klausz K; Kellner C; Bultmann M; Bastian L; Vogiatzi F; Leusen JHW; Burger R; Schewe DM; Peipp M; Valerius T
    Front Immunol; 2022; 13():949140. PubMed ID: 36052078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
    Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
    Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
    Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
    Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A; Van der Burg SH; Scheeren FA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.
    Evers M; Rösner T; Dünkel A; Jansen JHM; Baumann N; Ten Broeke T; Nederend M; Eichholz K; Klausz K; Reiding K; Schewe DM; Kellner C; Peipp M; Leusen JHW; Valerius T
    Blood Adv; 2021 Oct; 5(19):3807-3820. PubMed ID: 34525171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
    Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
    MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
    Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
    Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The CD47-SIRPα Immune Checkpoint.
    Logtenberg MEW; Scheeren FA; Schumacher TN
    Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 52. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is CD47 an innate immune checkpoint for tumor evasion?
    Liu X; Kwon H; Li Z; Fu YX
    J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.
    Jain S; Van Scoyk A; Morgan EA; Matthews A; Stevenson K; Newton G; Powers F; Autio A; Louissaint A; Pontini G; Aster JC; Luscinskas FW; Weinstock DM
    Blood; 2019 Oct; 134(17):1430-1440. PubMed ID: 31383641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index.
    Yang Y; Guo R; Chen Q; Liu Y; Zhang P; Zhang Z; Chen X; Wang T
    Biotechnol Lett; 2018 May; 40(5):789-795. PubMed ID: 29600425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
    Seckinger A; Buatois V; Moine V; Daubeuf B; Richard F; Chatel L; Viandier A; Bosson N; Rousset E; Masternak K; Salgado-Pires S; Batista C; Mougin C; Juan-Bégeot F; Poitevin Y; Hose D
    Front Immunol; 2024; 15():1378813. PubMed ID: 38720892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells.
    Bahri M; Kailayangiri S; Vermeulen S; Galopin N; Rossig C; Paris F; Fougeray S; Birklé S
    Cancer Immunol Immunother; 2022 Jan; 71(1):71-83. PubMed ID: 34023958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.